Parkman Healthcare Partners LLC Invests $1.91 Million in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Parkman Healthcare Partners LLC purchased a new position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 350,000 shares of the company's stock, valued at approximately $1,908,000. Parkman Healthcare Partners LLC owned about 0.14% of Maravai LifeSciences at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of MRVI. Performa Ltd US LLC raised its position in shares of Maravai LifeSciences by 614.3% in the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company's stock worth $27,000 after purchasing an additional 4,300 shares during the last quarter. FNY Investment Advisers LLC raised its position in Maravai LifeSciences by 600.0% in the 4th quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company's stock worth $38,000 after buying an additional 6,000 shares during the last quarter. Farther Finance Advisors LLC raised its position in Maravai LifeSciences by 3,541.4% in the 4th quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company's stock worth $56,000 after buying an additional 9,916 shares during the last quarter. Cibc World Markets Corp purchased a new position in Maravai LifeSciences in the 4th quarter worth about $56,000. Finally, Atria Investments Inc purchased a new position in Maravai LifeSciences in the 4th quarter worth about $58,000. Hedge funds and other institutional investors own 50.25% of the company's stock.

Analyst Ratings Changes

MRVI has been the subject of several research reports. UBS Group reduced their price target on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating for the company in a research report on Friday, March 21st. Robert W. Baird dropped their price target on Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a research note on Tuesday. Craig Hallum dropped their price target on Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday. Stifel Nicolaus set a $5.00 price target on Maravai LifeSciences in a research note on Friday, March 21st. Finally, Bank of America dropped their price target on Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating for the company in a research note on Monday, March 3rd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $6.64.

Maravai LifeSciences Stock Down 2.8%

NASDAQ MRVI opened at $2.06 on Wednesday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74. The company has a market capitalization of $523.93 million, a P/E ratio of -1.26 and a beta of 0.19. Maravai LifeSciences Holdings, Inc. has a one year low of $1.67 and a one year high of $11.56. The stock has a 50 day moving average price of $2.14 and a 200-day moving average price of $4.14.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The firm had revenue of $46.85 million for the quarter, compared to the consensus estimate of $44.01 million. Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. The company's quarterly revenue was down 26.9% on a year-over-year basis. As a group, equities analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current fiscal year.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.